A clinical decision support system for predicting drug-related adverse effects in pediatric patients with congenital heart disease: Development and retrospective evaluation
Open Access
- 1 July 2026
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 54 (7)
Abstract
Objective: Children with congenital heart disease are highly vulnerable to drug-related adverse effects due to the use of complex polypharmacy. This study aimed to develop and retrospectively evaluate a hybrid clinical decision support system for predicting drug-related adverse effects in this population. Methods: This two-phase study combined machine-learning techniques and expert clinical rules. Phase 1 included a retrospective analysis of 4651 pediatric congenital heart disease reports from the Food and Drug Administration Adverse Event Reporting System to train and compare five machine-learning models. The best-performing model, Random Forest, was selected. In Phase 2, a hybrid clinical decision support system integrating the Random Forest model with an expert-validated rule-based engine was developed and retrospectively evaluated using 330 inpatient records of pediatric patients with congenital heart disease. Results: The Random Forest model achieved a mean area under the receiver operating characteristic curve of 0.902. During clinical validation, the hybrid clinical decision support system demonstrated a mean accuracy of 0.85 across 11 common drug–adverse effect pairs, outperforming standalone machine-learning– and rule-based approaches. This study demonstrated the feasibility and clinical fidelity of using a hybrid clinical decision support system for predicting drug-related adverse effects in pediatric patients with congenital heart disease, supporting safer and more personalized pharmacotherapy. Conclusions: This study demonstrated the feasibility and clinical fidelity of using a hybrid clinical decision support system for predicting drug-related adverse effects in pediatric patients with congenital heart disease, supporting safer and more personalized pharmacotherapy.Keywords
Funding Information
- Iran University of Medical Sciences (1402-2-113-26934)
This publication has 35 references indexed in Scilit:
- Drug‐Related Side Effects and Contributing Risk Factors in Children With Congenital Heart Disease: A Cross‐Sectional StudyHealth Science Reports, 2025
- Combining machine learning models and rule engines in clinical decision systems: Exploring optimal aggregation methods for vaccine hesitancy predictionComputers in Biology and Medicine, 2025
- Application of machine learning in drug side effect prediction: databases, methods, and challengesFrontiers of Computer Science, 2024
- Adverse Drug Reactions in Children with Congenital Heart Disease: A Scoping ReviewPediatric Drugs, 2024
- Taxonomy of hybrid architectures involving rule-based reasoning and machine learning in clinical decision systems: A scoping reviewJournal of Biomedical Informatics, 2023
- Improving long-term care and outcomes of congenital heart disease: fulfilling the promise of a healthy lifeThe Lancet Child & Adolescent Health, 2023
- Assessment of a hybrid decision support system using machine learning with artificial intelligence to safely rule out prescriptions from medication review in daily practiceInternational Journal of Clinical Pharmacy, 2022
- Hybrid Method Incorporating a Rule-Based Approach and Deep Learning for Prescription Error PredictionDrug Safety, 2021
- Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?The Journal of Clinical Pharmacology, 2021
- A similarity-based method for prediction of drug side effects with heterogeneous informationMathematical Biosciences, 2018